Biotech Values

[flatlander_60048]

NVS keeps plugging away at trying to get into the HCV race.
I guess the space is too compelling despite the history of setbacks with IDIX and HGSI. Does anyone know whether the new drug class "cyclophilin inhibitor" has potential as a cocktail. The attached study looks like it was only evaluated in combination with the current SOC.

FL

http://www.novartis.com/newsroom/media-releases/en/2011/1502270.shtml